Annual CFI
-$3.21 B
+$1.28 B+28.50%
31 March 2024
Summary:
Takeda Pharmaceutical Company Limited annual cash flow from investing activities is currently -$3.21 billion, with the most recent change of +$1.28 billion (+28.50%) on 31 March 2024. During the last 3 years, it has fallen by -$6.93 billion (-186.59%). TAK annual CFI is now -186.59% below its all-time high of $3.71 billion, reached on 31 March 2021.TAK Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$555.58 M
+$449.57 M+44.73%
01 September 2024
Summary:
Takeda Pharmaceutical Company Limited quarterly cash flow from investing activities is currently -$555.58 million, with the most recent change of +$449.57 million (+44.73%) on 01 September 2024. Over the past year, it has dropped by -$233.38 million (-72.43%). TAK quarterly CFI is now -116.06% below its all-time high of $3.46 billion, reached on 30 September 2019.TAK Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$2.51 B
-$233.38 M-10.25%
01 September 2024
Summary:
Takeda Pharmaceutical Company Limited TTM cash flow from investing activities is currently -$2.51 billion, with the most recent change of -$233.38 million (-10.25%) on 01 September 2024. Over the past year, it has increased by +$3.37 billion (+57.29%). TAK TTM CFI is now -167.63% below its all-time high of $3.71 billion, reached on 31 March 2021.TAK TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TAK Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.5% | -72.4% | +57.3% |
| 3 y3 years | -186.6% | -88.1% | -200.1% |
| 5 y5 years | +87.4% | -116.1% | +88.8% |
TAK Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -186.6% | +28.5% | -266.5% | +83.2% | -200.1% | +58.3% |
| 5 y | 5 years | -186.6% | +87.4% | -116.1% | +83.2% | -167.6% | +88.8% |
| alltime | all time | -186.6% | +87.4% | -116.1% | +96.1% | -167.6% | +90.3% |
Takeda Pharmaceutical Company Limited Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$555.58 M(-44.7%) | -$2.51 B(+10.2%) |
| June 2024 | - | -$1.01 B(+105.4%) | -$2.28 B(-29.2%) |
| Mar 2024 | -$3.21 B(-28.5%) | -$489.35 M(+6.2%) | -$3.21 B(-46.6%) |
| Dec 2023 | - | -$460.58 M(+42.9%) | -$6.03 B(+2.5%) |
| Sept 2023 | - | -$322.20 M(-83.4%) | -$5.88 B(+3.0%) |
| June 2023 | - | -$1.94 B(-41.1%) | -$5.71 B(+26.9%) |
| Mar 2023 | -$4.50 B(+154.8%) | -$3.30 B(+952.9%) | -$4.50 B(+211.5%) |
| Dec 2022 | - | -$313.42 M(+106.7%) | -$1.44 B(-15.5%) |
| Sept 2022 | - | -$151.60 M(-79.3%) | -$1.71 B(-7.8%) |
| June 2022 | - | -$730.96 M(+195.4%) | -$1.85 B(+5.0%) |
| Mar 2022 | -$1.76 B(-147.5%) | -$247.48 M(-57.2%) | -$1.76 B(-242.8%) |
| Dec 2021 | - | -$578.38 M(+95.8%) | $1.24 B(-50.7%) |
| Sept 2021 | - | -$295.38 M(-54.1%) | $2.51 B(-18.1%) |
| June 2021 | - | -$643.58 M(-123.4%) | $3.06 B(-17.5%) |
| Mar 2021 | $3.71 B(+38.1%) | $2.75 B(+297.0%) | $3.71 B(+186.9%) |
| Dec 2020 | - | $693.45 M(+166.9%) | $1.29 B(-1120.3%) |
| Sept 2020 | - | $259.79 M(+4122.9%) | -$126.82 M(-104.1%) |
| June 2020 | - | $6.15 M(-98.2%) | $3.07 B(+14.3%) |
| Mar 2020 | $2.69 B(-110.5%) | $334.60 M(-146.0%) | $2.69 B(-130.2%) |
| Dec 2019 | - | -$727.37 M(-121.0%) | -$8.91 B(-60.4%) |
| Sept 2019 | - | $3.46 B(-1013.8%) | -$22.48 B(-12.9%) |
| June 2019 | - | -$378.52 M(-96.6%) | -$25.80 B(+0.9%) |
| Mar 2019 | -$25.58 B(+2936.2%) | -$11.26 B(-21.2%) | -$25.58 B(+67.3%) |
| Dec 2018 | - | -$14.30 B(<-9900.0%) | -$15.28 B(+1327.4%) |
| Sept 2018 | - | $137.47 M(-187.7%) | -$1.07 B(-43.4%) |
| June 2018 | - | -$156.69 M(-83.8%) | -$1.89 B(+124.7%) |
| Mar 2018 | -$842.45 M(-86.1%) | -$968.00 M(+1058.6%) | -$842.45 M(-84.9%) |
| Dec 2017 | - | -$83.55 M(-87.8%) | -$5.57 B(-3.0%) |
| Sept 2017 | - | -$684.96 M(-176.6%) | -$5.75 B(+12.3%) |
| June 2017 | - | $894.05 M(-115.7%) | -$5.12 B(-15.6%) |
| Mar 2017 | -$6.06 B | -$5.70 B(+2101.2%) | -$6.06 B(+4138.0%) |
| Dec 2016 | - | -$258.79 M(+361.1%) | -$143.07 M(-61.0%) |
| Sept 2016 | - | -$56.13 M(+8.0%) | -$366.59 M(-23.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$51.98 M(-123.2%) | -$477.58 M(-19.5%) |
| Mar 2016 | -$593.40 M(-171.0%) | $223.83 M(-146.4%) | -$593.40 M(-33.1%) |
| Dec 2015 | - | -$482.31 M(+188.6%) | -$886.37 M(-447.2%) |
| Sept 2015 | - | -$167.11 M(-0.4%) | $255.31 M(-32.6%) |
| June 2015 | - | -$167.81 M(+142.7%) | $378.73 M(-54.7%) |
| Mar 2015 | $835.33 M(-154.3%) | -$69.13 M(-110.5%) | $835.33 M(+5.3%) |
| Dec 2014 | - | $659.36 M(-1609.1%) | $793.48 M(-169.2%) |
| Sept 2014 | - | -$43.69 M(-115.1%) | -$1.15 B(+5.5%) |
| June 2014 | - | $288.79 M(-360.2%) | -$1.09 B(-29.4%) |
| Mar 2014 | -$1.54 B(-3.0%) | -$110.98 M(-91.3%) | -$1.54 B(+7.8%) |
| Dec 2013 | - | -$1.28 B(-7897.5%) | -$1.43 B(+871.7%) |
| Sept 2013 | - | $16.42 M(-110.1%) | -$146.88 M(-10.1%) |
| June 2013 | - | -$163.30 M(+672.5%) | -$163.30 M(-85.8%) |
| Mar 2013 | -$1.59 B(-88.6%) | - | - |
| Mar 2012 | -$13.86 B(+1102.4%) | - | - |
| Mar 2011 | -$1.15 B(-9.0%) | -$21.14 M(-94.8%) | -$1.15 B(-33.4%) |
| Dec 2010 | - | -$403.51 M(-18.9%) | -$1.73 B(+9.8%) |
| Sept 2010 | - | -$497.71 M(+116.0%) | -$1.58 B(+24.5%) |
| June 2010 | - | -$230.38 M(-61.6%) | -$1.27 B(-0.0%) |
| Mar 2010 | -$1.27 B(-83.6%) | -$600.29 M(+141.5%) | -$1.27 B(+90.1%) |
| Dec 2009 | - | -$248.53 M(+32.6%) | -$666.30 M(+59.5%) |
| Sept 2009 | - | -$187.37 M(-18.7%) | -$417.78 M(+81.3%) |
| June 2009 | - | -$230.41 M | -$230.41 M |
| Mar 2009 | -$7.72 B(-964.2%) | - | - |
| Mar 2008 | $892.88 M(-10.3%) | - | - |
| Mar 2007 | $995.64 M(+1614.5%) | - | - |
| Mar 2006 | $58.07 M(-108.6%) | - | - |
| Mar 2005 | -$673.77 M(-45.5%) | - | - |
| Mar 2004 | -$1.24 B(-207.4%) | - | - |
| Mar 2003 | $1.15 B(+14.8%) | - | - |
| Mar 2002 | $1.00 B(-290.0%) | - | - |
| Mar 2001 | -$527.85 M(+13.3%) | - | - |
| Mar 2000 | -$465.96 M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual cash flow from investing activities?
- What is the all time high annual CFI for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual CFI year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly CFI year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM cash flow from investing activities?
- What is the all time high TTM CFI for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM CFI year-on-year change?
What is Takeda Pharmaceutical Company Limited annual cash flow from investing activities?
The current annual CFI of TAK is -$3.21 B
What is the all time high annual CFI for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual cash flow from investing activities is $3.71 B
What is Takeda Pharmaceutical Company Limited annual CFI year-on-year change?
Over the past year, TAK annual cash flow from investing activities has changed by +$1.28 B (+28.50%)
What is Takeda Pharmaceutical Company Limited quarterly cash flow from investing activities?
The current quarterly CFI of TAK is -$555.58 M
What is the all time high quarterly CFI for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly cash flow from investing activities is $3.46 B
What is Takeda Pharmaceutical Company Limited quarterly CFI year-on-year change?
Over the past year, TAK quarterly cash flow from investing activities has changed by -$233.38 M (-72.43%)
What is Takeda Pharmaceutical Company Limited TTM cash flow from investing activities?
The current TTM CFI of TAK is -$2.51 B
What is the all time high TTM CFI for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM cash flow from investing activities is $3.71 B
What is Takeda Pharmaceutical Company Limited TTM CFI year-on-year change?
Over the past year, TAK TTM cash flow from investing activities has changed by +$3.37 B (+57.29%)